{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:55:25Z","timestamp":1790193325102,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.4065\/mcp.2010.0636","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T03:54:37Z","timestamp":1299729277000},"page":"338-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Update on Medications With Adverse Skeletal Effects"],"prefix":"10.4065","volume":"86","author":[{"given":"Caroline J. Davidge","family":"Pitts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.4065\/mcp.2010.0636_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.4065\/mcp.2010.0636_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","article-title":"Effects of low-dose prednisone on bone metabolism","volume":"20","author":"Ton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.4065\/mcp.2010.0636_bib3","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.4065\/mcp.2010.0636_bib4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.4065\/mcp.2010.0636_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"issue":"11","key":"10.4065\/mcp.2010.0636_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"10.4065\/mcp.2010.0636_bib7","first-page":"2239","article-title":"Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures","volume":"83","author":"Ettinger","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4065\/mcp.2010.0636_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"17","author":"Heshmati","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.4065\/mcp.2010.0636_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"issue":"19","key":"10.4065\/mcp.2010.0636_bib10","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.4065\/mcp.2010.0636_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.4065\/mcp.2010.0636_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.4065\/mcp.2010.0636_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.4065\/mcp.2010.0636_bib14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"issue":"2","key":"10.4065\/mcp.2010.0636_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.contraception.2007.10.005","article-title":"Bone density recovery after depot medroxyprogesterone acetate injectable contraception","volume":"77","author":"Kaunitza","year":"2007","journal-title":"Contraception"},{"issue":"4","key":"10.4065\/mcp.2010.0636_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/jc.2007-2201","article-title":"Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study","volume":"93","author":"Walsh","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.4065\/mcp.2010.0636_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.whi.2006.09.003","article-title":"Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities","volume":"16","author":"Watson","year":"2006","journal-title":"Womens Health Issues"},{"issue":"6","key":"10.4065\/mcp.2010.0636_bib18","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.4065\/mcp.2010.0636_bib19","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.4065\/mcp.2010.0636_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"31","key":"10.4065\/mcp.2010.0636_bib21","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.4065\/mcp.2010.0636_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.4065\/mcp.2010.0636_bib23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/mcp.2010.0636_bib24","first-page":"416","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.4065\/mcp.2010.0636_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"issue":"8","key":"10.4065\/mcp.2010.0636_bib26","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.4065\/mcp.2010.0636_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.4065\/mcp.2010.0636_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bone.2010.05.038","article-title":"Treatment and prevention of bone complications from prostate cancer","volume":"48","author":"Lee","year":"2011","journal-title":"Bone"},{"issue":"10","key":"10.4065\/mcp.2010.0636_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-152-10-201005180-00002","article-title":"Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer","volume":"152","author":"Ito","year":"2010","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0636_bib30","first-page":"S241","article-title":"Effects of thiazolidinediones on bone turnover in the rat [Abstract]","volume":"10","author":"Jennermann","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"23","key":"10.4065\/mcp.2010.0636_bib31","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387-1388]","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/mcp.2010.0636_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1172\/JCI111254","article-title":"An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium","volume":"73","author":"Bo-Linn","year":"1984","journal-title":"J Clin Invest"},{"issue":"8","key":"10.4065\/mcp.2010.0636_bib33","first-page":"1376","article-title":"Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects","volume":"10","author":"Graziani","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.4065\/mcp.2010.0636_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.4065\/mcp.2010.0636_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"24","key":"10.4065\/mcp.2010.0636_bib36","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.4065\/mcp.2010.0636_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","article-title":"Increase in vertebral fracture risk in postmenopausal women using omeprazole","volume":"84","author":"Roux","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.4065\/mcp.2010.0636_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults","volume":"83","author":"Yu","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.4065\/mcp.2010.0636_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/en.2004-1259","article-title":"Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth","volume":"146","author":"Warden","year":"2005","journal-title":"Endocrinology"},{"issue":"2","key":"10.4065\/mcp.2010.0636_bib40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","article-title":"Effect of selective serotonin reupdate inhibitors on the risk of fracture","volume":"167","author":"Richards","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/mcp.2010.0636_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e31817e0ecb","article-title":"Selective serotonin reuptake inhibiting antidepressants are associated with increased risk of nonvertebral fractures","volume":"28","author":"Ziere","year":"2008","journal-title":"J Clin PsychoPharmacol"},{"issue":"12","key":"10.4065\/mcp.2010.0636_bib42","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archinte.167.12.1240","article-title":"Use of antidepressants and rates of hip bone loss in older women","volume":"167","author":"Diem","year":"2007","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.4065\/mcp.2010.0636_bib43","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinte.167.12.1246","article-title":"Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men","volume":"167","author":"Haney","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.4065\/mcp.2010.0636_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/YIC.0b013e3282f2b3bb","article-title":"Selective serotonin reuptake inhibitor use and bone mineral density in women with history of depression","volume":"23","author":"Williams","year":"2008","journal-title":"Int Clin PsychoPharmacol"},{"issue":"3","key":"10.4065\/mcp.2010.0636_bib45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bone.2010.06.006","article-title":"Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures","volume":"47","author":"Verdel","year":"2010","journal-title":"Bone"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611600116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611600116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T04:57:20Z","timestamp":1675918640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611600116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0025619611600116"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0636","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Medications With Adverse Skeletal Effects","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2010.0636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}